Agaphelin modulates the activation of human bronchial epithelial cells induced by lipopolysaccharide and IL-4

Daniely Cornélio Favarin, Aline Beatriz Mahler Pereira, Ivo M.B. Francischetti, Marcos Vinicius da Silva, Virmondes Rodrigues, Paulo Roberto da Silva, Jesus G. Valenzuela, David Nascimento Silva Teixeira, Carlo José Freire Oliveira, Alexandre de Paula Rogério

Research output: Contribution to journalArticlepeer-review

Abstract

Sand fly saliva presents molecules with potential to development of compounds for treatment of inflammatory diseases. Agaphelin, isolated from the saliva of the mosquito Anopheles gambiae, demonstrates anti-inflammatory properties such as neutrophils chemotaxis inhibition. Here, we extend these results and evaluated the role of agaphelin (0.1−100 nM) in an in vitro model consisting in the activation of human bronchial epithelial cells (BEAS-2B) by IL-4 (50 ng/mL) or lipopolysaccharide (LPS; 10 ng/mL). Agaphelin is non-cytotoxic for BEAS-2B cells. Notably, agaphelin markedly reduces CCL2 and IL-8 production induced by IL-4 or LPS, without altering the IL-10 production. The TLR4 expression and STAT1 phosphorylation induced by LPS were inhibited by agaphlin. In addition, agaphelin decreased the phosphorylation of STAT6 induce by IL-4, whose effect was independent of IL-4-binding activity. Taken together, these findings identify agaphelin as a potential anti-inflammatory therapeutic agent for airway inflammations.

Original languageEnglish (US)
Article number151937
JournalImmunobiology
Volume225
Issue number3
DOIs
StatePublished - May 2020
Externally publishedYes

Keywords

  • Agaphelin
  • Bronchial epithelial cells
  • IL-4
  • LPS

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Fingerprint Dive into the research topics of 'Agaphelin modulates the activation of human bronchial epithelial cells induced by lipopolysaccharide and IL-4'. Together they form a unique fingerprint.

Cite this